Reference Detail

Ref Type

PMID

Authors

Patrick Mayes, Paul Tacken, Steve Wang, Pieter-Fokko van Loo, Thomas Condamine, Hans van der Maaden, Eric Rovers, Steef Engels, Floris Fransen, Ashwini Kulkarni, Yao-bin Liu, Arpita Mondal, Leslie Hall, Soyeon Kim, Marina Martinez, Shaun O'Brien, Edmund Moon, Steven Albelda, Peggy Scherle, Gregory Hollis, Reid Huber, Mark Throsby, Cecile A. Geuijen.

Title

A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

https://cancerres.aacrjournals.org/content/79/13_Supplement/539

Abstract Text

Cancer Res 2019;79(13 Suppl):Abstract nr 539

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
MCLA-145	MCLA-145	2	1

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
MCLA-145		MCLA145\|MCLA 145\|anti-PD-L1/4-1BB bispecific antibody	Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 TNFRSF9 Antibody 32	MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
CD274 positive	lung cancer	predicted - sensitive	MCLA-145	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MCLA-145 treatment inhibited tumor growth in a cell line xenograft model of CD274 (PD-L1) and NY-ESO-positive lung cancer that had adoptive transfer of human T-cells expressing NY-ESO specific T-cell receptors (Cancer Res 2019;79(13 Suppl):Abstract nr 539).	detail...